Smith Family Clinic for Genomic Medicine’s Post

Biomarkers Market Size To Hit USD 93.8 Billion by 2029 Download Free Sample Report-https://lnkd.in/dmKwWDPH The size of global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. Companies Working in the Market Tecan Immatics Nordic Bioscience   Medicines Discovery Catapult Ad Scientiam IXICO Oncodesign Services Quibim Universal Diagnostics S.A. Centre for Human Drug Research Olink Proteomics TRON-Mainz Takis Beats Medical Citoxlab, a Charles River Company BioSerenity Fios Genomics Idoven Rockley Photonics  Radiomics.bio Pelago Bioscience AB OncoDNA Bioneer A/S     iLoF Indivi BioArctic Optics11 Life Brainomix EATRIS Amadix Fujirebio Europe PrecisionLife Aiforia Technologies Pear Bio Anaxomics Biotech S.L. Fundacion MEDINA Definiens, The Tissue Phenomics Company Microbiotica     Engitix Therapeutics

Biomarkers Market Size To Hit USD 93.8 Billion by 2029 Download Free Sample Report-https://lnkd.in/dmKwWDPH The size of global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. Companies Working in the Market Tecan Immatics Nordic Bioscience   Medicines Discovery Catapult Ad Scientiam IXICO Oncodesign Services Quibim Universal Diagnostics S.A. Centre for Human Drug Research Olink Proteomics TRON-Mainz Takis Beats Medical Citoxlab, a Charles River Company BioSerenity Fios Genomics Idoven Rockley Photonics  Radiomics.bio Pelago Bioscience AB OncoDNA Bioneer A/S     iLoF Indivi BioArctic Optics11 Life Brainomix EATRIS Amadix Fujirebio Europe PrecisionLife Aiforia Technologies Pear Bio Anaxomics Biotech S.L. Fundacion MEDINA Definiens, The Tissue Phenomics Company Microbiotica     Engitix Therapeutics

Our Services Include: 🧬 In Vitro Cytotoxicity Assays: Evaluate the effectiveness of potential anticancer compounds using cutting-edge techniques. 🔍 Cell Proliferation and Apoptosis Studies: Understand the mechanisms of cancer cell growth and programmed cell death. 🌟 Genomic and Proteomic Analysis: Explore genetic and protein expression profiles to identify biomarkers and therapeutic targets. 💊 Drug Screening and Efficacy Testing: Screen and validate novel anticancer agents for potential therapeutic use. Why Choose Us? ✅ Expert Team: Our skilled scientists have extensive experience in cancer research and drug development. ✅ Advanced Technology: We utilize the latest tools and methodologies to deliver accurate and reliable results. ✅ Customized Solutions: Tailored services to meet the specific needs of your research and development projects. Additional Services: 🚀 Product Development Assistance for Startups: Helping you bring your innovative ideas to market. 🎓 Research Assistance for Academic Projects: Supporting academic researchers with comprehensive analytical services. Join us in the fight against cancer and accelerate your research with Athmic Biotech Solutions Pvt Ltd. 📞 +91 884-8185240(WhatsApp) Contact us today to learn more about our services and how we can assist you in your anticancer research journey. #CancerResearch #Biotech #LifeSciences #DrugDevelopment #Anticancer #Innovation #Research #Startups #AcademicResearch by

Mutation Detection Kits In Genome Editing Market Size, Share & Trends Analysis Report By Application (CRISPR/Cas9 {Genetically Modified Organisms (GMO) Analysis, Disease Genotyping, Typing of Transgenic Plants, Therapy Development, Epigenetic Editing}ZFN {Genetically Modified Organisms (GMO) Analysis, Disease Genotyping, Typing of Transgenic Plants, Therapy Development, Epigenetic Editing}), By TALENs/MegaTALs (Genetically Modified Organisms (GMO) Analysis, Disease Genotyping, Typing Of Transgenic Plants, Therapy Development, Epigenetic Editing), By Meganucleases (Genetically Modified Organisms (GMO) Analysis, Disease Genotyping, Typing of Transgenic Plants, Therapy Development, Epigenetic Editing, Others), By End-use (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 🌐IMIR Market Research Pvt. Ltd. 📚𝐀𝐜𝐜𝐞𝐬𝐬 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: 👇 https://lnkd.in/gygxa9YE 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞:👇 4basebio Addgene Agilent Technologies Alia Therapeutics Amoy Diagnostics Applied Materials BDG LifeSciences Beam Therapeutics Bio-Rad Laboratories BioVision, an Abcam company Bluebird Caribou Cellectis Creative Artists Agency CRISPR Therapeutics DiBio - Dipartimento di Biologia - Università di Padova EdiGene Inc. Editas Medicine ERS Genomics GeneGoCell Inc. GenScript Integrated Resources, Inc ( IRI ) Intellias InVivo Biosystems Launch Diagnostics Limited Life Edit Therapeutics LogicBio Therapeutics Lonza Lucigen Corp. Medaysis Merck KGaA, Darmstadt, Germany Mylab Discovery Solutions Pvt. Ltd. New England Biolabs OriGene PerkinElmer, Precision BioSciences, Inc. Promega Corporation Recombia Biosciences Recombinetics #mutation #art #effetspersonnels #groupage #maritime #moto #voiture #martinique #demenagement #transport #dom #caraibes #container #domtom #logistique #colis #madinia #lefrancois #fortdefrance #antilles #fret #retaite #demenage #demenager #exportation #expatrie #vehicule #d #mutant #punk

@research highlights @project proposal @antimicrobial resistance Targeted silver nanoparticles nanozyme therapy for helicobacter pylori eradication utilizing anti CagA antibodies for specific targeting and liposomes as carrier systems project proposal aimed at using nanozymes specifically silver nanoparticles to disrupt the cell wall intergrity by degrading the peptidoglycan layer leading to cell lysis of the bacteria. anti CagA antibodies are used to recognize and bind to the h.pylori ensuring target and delivery. liposomes are used as carrier systems because they are biocompatible and biodegradable.

📃Identification of MeC3HDZ1/MeCNA as a potential regulator of cassava storage root development 👥Solé-Gil A, Lopez A, Ombrosi D, Urbez C, Brumós J, Agustí J The storage root (SR) of cassava is the main staple food in sub-Saharan Africa, where it feeds over 500 million people. However, little is known about the genetic and molecular regulation underlying its development. Unraveling such regulation would pave the way for biotechnology approaches aimed at enhancing cassava productivity. Anatomical studies indicate that SR development relies on the massive accumulation of xylem parenchyma, a cell-type derived from the vascular cambium. The C3HDZ family of transcription factors regulate cambial cells proliferation and xylem differentiation in Arabidopsis and other species. We thus aimed at identifying C3HDZ proteins in cassava and determining whether any of them shows preferential activity in the SR cambium and/or xylem. Using phylogeny and synteny studies, we identified eight C3HDZ proteins in cassava, namely MeCH3DZ1–8. We observed that MeC3HDZ1 is the MeC3HDZ gene displaying the highest expression in SR and that, within that organ, the gene also shows high expression in cambium and xylem. In-silico analyses revealed the existence of a number of potential C3HDZ targets displaying significant preferential expression in the SR. Subsequent Y1H analyses proved that MeC3HDZ1 can bind canonical C3HDZ binding sites, present in the promoters of these targets. Transactivation assays demonstrated that MeC3HDZ1 can regulate the expression of genes downstream of promoters harboring such binding sites, thereby demonstrating that MeC3HDZ1 has C3HDZ transcription factor activity. We conclude that MeC3HDZ1 may be a key factor for the regulation of storage root development in cassava, holding thus great promise for future biotechnology applications. 🔗https://lnkd.in/dbwV5RzJ #paperIBMCP

It is amazing to see @Nature Biotechnology cover this critical topic of reducing costs and improving access to breakthrough #cellandgenetherapy in LMICs amazing piece by Ben Johnson. The article highlights several promising initiatives from India - by ImmunoACT (Rahul Purwar), Imuneel (Arun Anand, MD) and IGIB (Debojyoti Chakraborty)- to develop more affordable versions of these cutting-edge treatments. Local IP ownership, scaling up local manufacturing capacity, and utilization of skilled yet economical workforces could be major advantages. However regulatory challenges pose a major hurdle. I'm optimistic that by encouraging more participation from LMICs in research and development - while addressing unique local needs and limitations - we can chart a sustainable path to make these life-saving therapies available to many more patients globally. Narendra Chirmule Dr. Gayatri Saberwal Dr Bhaskar Jyoti Sonowal Arkasubhra Ghosh tagging you as this might be of interest to you.

💊 𝗡𝗮𝗻𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆-𝗯𝗮𝘀𝗲𝗱 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀: 𝟱 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵! 👀 🔵 The growing use of nanotechnology in drug delivery is transforming healthcare by allowing for targeted, efficient, and controlled release of medications! 🔵 These young companies are great examples of startups leading the way in this transformation, developing state-of-the-art technologies that improve the precision and effectiveness of treatments! 🔵 From targeted cancer treatments to advanced gene therapies, these startups are laying the groundwork for a new era in medicine! 🔵 Take a look through the startups in our list: 💠 Aera Therapeutics 💠 Orion Therapeutics, Inc. 💠 NanoPhoria 💠 NanoVation Therapeutics™ 💠 Mana.bio ---------------------------------------------- What startups can you add to the list? Source: VentureRadar #startup #drugdelivery #lipidnanoparticle #LNP #liposome #biotechnology #biopharmaindustry #nanotechnology

A really outstanding explanation of the concept and application of epigenetics. This is related to, but different than gene editing. You may not be able to access without a subscription to the Wall Street Journal... It ain't cheap, but it's the cheapest MBA program you'll ever enter. Your return on investment will be high. (Yes, I'm a WSJ fanboy....) #epigenetics #Biotech #biotechinnovation Moonwalk Bio Grabs $57 Million, Joins Push for ‘Epigenetic’ Treatments https://lnkd.in/exUr4RbH

🔬 Are you an expert in eukaryotic cell cultures? A global fortune 500 company is seeking proven methods to increase the viral yield from eukaryotic cell cultures in vitro, with particular interest in increasing the yield of Morbilliviruses in established cell lines. Available partnership models include co-development, acquisition, supply/purchase, licensing, and material transfer. Solutions of interest include: - Novel methods to improve yield of Morbillivirus or closely related viruses from any eukaryotic cell lines - Cell culture media or supplements to increase/enhance viral yield - Solutions for increasing virus secretion or release into cell culture media from infected cells - Scalable approaches to increase the concentration of live viral fluids - Optimized cell lines with reduced interference / defense mechanisms that can inhibit replication The deadline to submit a proposal for consideration is December 31st. Submit your proposal now 👉  https://lnkd.in/gAQTEjt4 #Biomedical #Biology #Virology #Startups #Innovation #Research #Startup